A new algorithm can predict total hip revisions

0

NEW ALGORITHM PREDICTS HIP JOINT REVISION (Orthopedics This Week)
Which patients are more likely to be readmitted to the hospital following hip replacement surgery? A study reported on by Irvin Jackson—a writer for About Lawsuits.com—and published in the journal AMA Surgery found that hip complications more frequently occur among older patients and those who are dealing with other health problems.
The study principals examined data on 268,518 patients from New York and California from 2006 through 2011. According to Jackson, they found that patients who were over the age of 74, African Americans, and patients suffering from congestive heart failure, liver disease, pulmonary disease, kidney failure, diabetes and other health problems were more likely to require revision surgery.
The researchers devised a scale to calculate the impact of these factors and found that the scale was able to predict the high-risk patients a majority of the time. They found that nearly 6% of patients who received a hip implant were readmitted within 30 days due to problems. Jackson noted that “complications from hip implants often include mechanical failures, poisoning from metallic debris from metal-on-metal implants, and surgical site infections.”

Read More

Zimmer-Biomet acquires Cayenne Medical

0

Multiple is 7.5 X sales – Word on the street says that Zimmer will pay $150M in total earnouts (3 payments) on $20M sales @ Cayenne in the last year. 
 
Zimmer Biomet Enters into Definitive Agreement to Acquire Cayenne Medical (press release)
WARSAW, Ind., April 25, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced today that it has entered into a definitive agreement to acquire Scottsdale, Arizona-based Cayenne Medical, Inc. The transaction, which is subject to customary closing conditions, is expected to close during the second quarter of 2016. The financial terms of the transaction were not disclosed.
The acquisition of Cayenne Medical will strengthen Zimmer Biomet’s Sports Medicine capabilities and portfolio of technically advanced soft tissue reconstruction solutions for knee, shoulder and extremities procedures.
“As a market leader in musculoskeletal healthcare, the expansion of our Sports Medicine business with Cayenne Medical’s highly successful portfolio represents an exciting growth opportunity and will meaningfully advance our commitment to serving the needs of patients across the full continuum of care,” said David Nolan, Group President of Zimmer Biomet’s Sports Medicine, Extremities, Trauma, Biologics and Surgical businesses. “With rising demand for the clinical benefits of advanced soft tissue repair and reconstruction solutions, we greatly look forward to leveraging Zimmer Biomet’s scale and specialized sales capabilities to broaden and accelerate the growth of Cayenne Medical’s clinically acclaimed offerings.”
“Cayenne Medical is extremely pleased to join forces with Zimmer Biomet to drive the future growth and ongoing development of our innovative sports medicine technologies,” said David B. Springer, President and Chief Executive Officer of Cayenne Medical. “From the beginning, Cayenne Medical has endeavored to be a leader in the soft tissue repair and reconstruction segment of sports medicine, and this combination with Zimmer Biomet will advance our mission to solve unmet needs in this clinical area, while transforming traditional techniques with minimally invasive innovations and generating compelling cost savings in the delivery of care by surgeons, surgery centers and hospitals.”
Advisors
Faegre Baker Daniels LLP is serving as legal counsel to Zimmer Biomet. Piper Jaffray is serving as exclusive financial advisor to Cayenne Medical and Snell & Wilmer is serving as its legal counsel.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation.  Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
About Cayenne Medical
Cayenne Medical designs, develops and markets technically advanced soft tissue reconstruction solutions for the knee, shoulder and extremities. Founded in 2005, the company has led the transformation of traditional arthroscopic procedures by applying innovative technology through minimally invasive techniques.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “aims,” “anticipates,” “plans,” “looks forward to,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “seeks” or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s anticipated acquisition of Cayenne Medical and the expected timing of closing and benefits of such acquisition; new product launches; regulatory approvals; product portfolio and performance; competitive offerings; market performance; business plans and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of these risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this communication.
Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO
SOURCE Zimmer Biomet Holdings, Inc.
Related Links
http://www.zimmerbiomet.com

Read More

A Spine company launches a new Foot and Ankle product

0

Centric Medical™ Announces Full Market Release of TARSA-LINK™ Stand-Alone Wedge Fixation System for Foot and Ankle (press release)
LIST of 26 Extremeties Startups
Centric Medical, a division of Life Spine Inc., announced the full market release of the Tarsa-Link Stand-Alone Wedge Fixation System for internal bone fracture fixation, fusion and osteotomy in the foot and ankle.
“The Tarsa-Link wedge is a powerful device that can be used to correct flatfoot deformities,” Gregory G.  Caronis, MD, of Greenleaf Orthopaedics & Physical Therapy located in Libertyville, Ill., said in a company press release. “It truly allows for the optimal amount of correction needed for each patient’s unique anatomy. Because the implant is made from a [polyetheretherketone] PEEK material, it provides greater stability than an allograft, while eliminating the risk of donor graft rejection. The implant’s design facilitates the use of screws that can be placed through the wedge, locking in the correction while providing a stable environment for fusion.”
According to the release, the Tarsa-Link is the first stand-alone osteotomy wedge with built-in fixation on the market.

Read More

Stryker acquires SafeWire for MIS needles in spine surgery

0

Stryker buys startup to bolster safety in minimally invasive spine surgery (Fierce Medical Devices)
Orthopedics implant and spine player Stryker has acquired Florida-based startup SafeWire in order to add to its minimally invasive spinal surgery products. Stryker has been on an M&A tear of late–this deal follows the closure of three acquisitions earlier this month.
Of SafeWire’s four products, Stryker highlighted two as of particular use to its Spine division: the Y-Wire guidewire and Tiger Jamshidi Needle Family. Y-Wire is designed to mitigate potential wire-based complications in minimally invasive spine surgery such as inadvertent advancement of the guidewire through bone, accidental pullout, kinking or wire migration.
Guidewires are standard in minimally invasive spine surgery, with almost all pedicle screw systems from these procedures requiring them to deliver screws and ensure their proper anatomical placement. SafeWire received a CE mark for Y-Wire in October 2014. It’s intended to enable fewer surgical steps as well as reduced exposure to fluoroscopy.
As for the Tiger needles, they are used for posterior fixation in minimally invasive spinal surgery. These, in particular, are designed to work with Y-Wire for bi- and tri-cortical fixation. They are intended to mitigate potential issues with impact advancement and back-out during these sorts of procedure. These were launched in the U.S. in September 2014 after an FDA clearance earlier that June.
“This acquisition increases our competitive advantage as we broaden our product line and extend our customer base among teaching facilities, competitive accounts, and existing SafeWire customers,” said Brad Paddock, president of Stryker’s Spine division, in a statement.
Stryker’s Spine business is one of its smaller and poorer performing units. The company just recently returned the business to growth–marking the third quarter of doing so in the fourth quarter.
“This marks our third consecutive quarter of strong growth in U.S. spine,” said Stryker chairman, President and CEO Kevin Lobo on the year-end earning call. “Spine also had a new 3D printed interbody device launching in 2016, which we believe will be a very exciting product for the market, helping us to continue this positive trend.”
– here is the release

Read More

Implanet's Jazz Lock is now cleared in the US and EU

0

IMPLANET: GREEN LIGHT(S) TO MARKET JAZZ LOCK (Orthopedics This Week)
IMPLANET has announced that it has the green light from the FDA—a 510k clearance—as well as the European CE mark for its new Jazz Lock implant. Let the marketing begin.
According to the April 5 2016 news release, “Jazz Lock is the first of an innovative range of band products designed for degenerative spine disorder surgery. This new implant expands the JAZZ technological platform and allows Implanet to broaden its activity to the cervical spine, estimated at over $200 million worldwide. Based on the polyester sublaminar braid platform, Jazz Lock eliminates the mechanism’s locking screw and connecting rod, thanks to a proprietary fastening locking system. Implanet thus offers surgeons a new implant with an optimized and reproducible surgical technique.”
Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, stated, “Constant innovation is the essential component in maintaining our technological advantage. Over the last two years, we have focused our efforts on finalizing our range of Jazz Band implants, notably with the market’s most extensive range of connectors, to ensure compatibility with all existing posterior fixation systems. A result of collaboration with leading surgeons, Jazz Lock represents a major breakthrough: an innovative, IP protected design offering surgeons a fusion device that no other company currently can.”
Implanet CEO Ludovic Lastennet added, “Obtaining regulatory clearances to market this new major component of our Jazz Band platform is a significant milestone in terms of product range expansion. Already established in the major spinal deformity segment, we are now accelerating our presence in the degenerative bone disorder segment, which is three times larger. Jazz Lock is the first component of an innovative range of band products for degenerative spine disorder surgery targeted for launch in the near future, in line with our execution plan. Jazz Lock’s commercial launch is underway and further expands the breadth of our product offering.”
Lastennet told OTW, “We have developed a polyester braid platform that allows for cerclage around bony structures such as lamina or transverse process. The same braid can be used for different spinal indications: deformations such as AIS [adolescent idiopathic scoliosis], trauma and degenerative surgeries. For each of these indications the surgeon can choose to use the braid with different types of connectors: JAZZ that connects to a rod and exists in 5 different diameters from 3.5 mm to 6.0 mm; JAZZ Lock that allows for wiring techniques without the use of a rod.”
“Over the next quarters, we will continue to launch new connectors to be integrated in this braid technology platform to address the deformity, degenerative and trauma vertebral fusion market.”

Read More

Technology, Startup News, Career Advice & More

Archives

Pin It on Pinterest

Menu